|
|
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| | #REDIRECT[[Clopidogrel]] |
| |authorTag={{SS}}
| |
| |genericName=Clopidogrel Bisulfate
| |
| |aOrAn=a
| |
| |drugClass=P2Y12 platelet inhibitor, Platelet aggregation inhibitor
| |
| |indication=[[acute coronary syndrome]] ([[ACS]]), recent [[MI]], recent [[stroke]], or established [[peripheral arterial disease]]
| |
| |hasBlackBoxWarning=Yes
| |
| |adverseReactions=non-major bleeding
| |
| |blackBoxWarningTitle=<span style="color:#FF0000;">WARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS</span>
| |
| |blackBoxWarningBody=* Effectiveness of clopidogrel depends on activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. (5.1)
| |
| * Poor metabolizers treated with clopidogrel at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function. (12.5)
| |
| * Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy. (12.5)
| |
| * Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers. (2.3, 5.1)
| |
| |fdaLIADAdult=<b>Condition 1</b>
| |
| | |
| * Dosing Information
| |
| | |
| :: (Dosage)
| |
| |offLabelAdultGuideSupport=<b>Condition 1</b>
| |
| | |
| * Developed by: (Organization)
| |
| | |
| * Class of Recommendation: (Class) (Link)
| |
| | |
| * Strength of Evidence: (Category A/B/C) (Link)
| |
| | |
| * Dosing Information/Recommendation
| |
| | |
| :* (Dosage)
| |
| |offLabelAdultNoGuideSupport=<b>Condition 1</b>
| |
| | |
| * Dosing Information
| |
| | |
| :* There is limited information about <i>Off-Label Non–Guideline-Supported Use</i> of Clopidogrel Bisulfate in adult patients.
| |
| |fdaLIADPed=<b>Condition 1</b>
| |
| | |
| * Dosing Information
| |
| | |
| :: (Dosage)
| |
| |offLabelPedGuideSupport=<b>Condition 1</b>
| |
| | |
| * Developed by: (Organization)
| |
| | |
| * Class of Recommendation: (Class) (Link)
| |
| | |
| * Strength of Evidence: (Category A/B/C) (Link)
| |
| | |
| * Dosing Information/Recommendation
| |
| | |
| :* (Dosage)
| |
| |offLabelPedNoGuideSupport=<b>Condition 1</b>
| |
| | |
| * Dosing Information
| |
| | |
| :* There is limited information about <i>Off-Label Non–Guideline-Supported Use</i> of Clopidogrel Bisulfate in pediatric patients.
| |
| |contraindications=* Condition 1
| |
| * Condition 2
| |
| * Condition 3
| |
| * Condition 4
| |
| * Condition 5
| |
| |warnings=<b>Conidition 1</b>
| |
| | |
| (Description)
| |
| |clinicalTrials=<b>Central Nervous System</b>
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| <b>Cardiovascular</b>
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| <b>Respiratory</b>
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| <b>Gastrointestinal</b>
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| <b>Hypersensitive Reactions</b>
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| <b>Miscellaneous</b>
| |
| | |
| : (list/description of adverse reactions)
| |
| |postmarketing=<b>Central Nervous System</b>
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| <b>Cardiovascular</b>
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| <b>Respiratory</b>
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| <b>Gastrointestinal</b>
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| <b>Hypersensitive Reactions</b>
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| <b>Miscellaneous</b>
| |
| | |
| : (list/description of adverse reactions)
| |
| |drugInteractions=* (Drug 1)
| |
| :* (Description)
| |
| | |
| * (Drug 2)
| |
| :* (Description)
| |
| | |
| * (Drug 3)
| |
| :* (Description)
| |
| |alcohol=Alcohol-Clopidogrel Bisulfate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
| |
| }}
| |